May. 11 at 12:29 PM
$ANIP Two takeaways from the earnings CC. ANIP is guiding around 21 % - 23% of Cortrophin 2026 sales is expected for Q2. Arguably that means Cortophin sales could reach
$200 million in Q4 as the acute gouty arthritis team gains traction. ANIP expect continued growth through 2027 and 2028. Using the Q4 sales alone as a run rate for 2027 would give ANIP
$800 million in Corti sales and rare disease drug sales approaching
$900 million.
Secondly, Stephen Carey 's response to a question, to my knowledge, was the first time they have ever mentioned the possibility of future dividends. The following was part of his response:
"Our shareholders should expect us to judiciously allocate cash between investment behind the strategic growth and diversification of the business, delevering our balance sheet and return of any excess capital to shareholders "
